A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
X. Cynthia(Washington University in St. Louis), Paula M. Fracasso(Jewish Hospital)
Cited by 107
Related Papers
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
|Journal of Clinical Investigation|2012|222
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
|Breast Cancer Research|2017|70
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
|Cancer Chemotherapy and Pharmacology|2010|69